Aadi Bioscience Inc (AADI)
1.94
+0.02
(+1.04%)
USD |
NASDAQ |
Oct 04, 16:00
1.94
0.00 (0.00%)
After-Hours: 20:00
Aadi Bioscience SG&A Expense (Annual): 44.55M for Dec. 31, 2023
SG&A Expense (Annual) Chart
Historical SG&A Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2023 | 44.55M |
| December 31, 2022 | 40.18M |
| Date | Value |
|---|---|
| December 31, 2021 | 18.51M |
| December 31, 2020 | 2.121M |
SG&A Expense Definition
SG&A expense (short for Selling, General and Administrative expense) is a line item on the income statement, though sometimes sales and marketing expenses are reported separately from general and administrative expenses.
SG&A Expense (Annual) Range, Past 5 Years
2.121M
Minimum
2020
44.55M
Maximum
2023
26.34M
Average
29.34M
Median
SG&A Expense (Annual) Benchmarks
| Bio-Path Holdings Inc | 4.235M |
| PROCEPT BioRobotics Corp | 131.77M |
| NovaBay Pharmaceuticals Inc | 12.83M |
| Palatin Technologies Inc | 12.27M |
| iBio Inc | 11.67M |